FDA – IDSA - ISAP Workshop April 15, 2004. Continuing Discussion on Incentives George H. Talbot MD On Behalf of the AATF. Presentation Objectives. Update workshop attendees on AATF’s efforts to clarify factors responsible for decreased antibacterial R&D
FDA – IDSA - ISAP WorkshopApril 15, 2004
Continuing Discussion on Incentives
George H. Talbot MD
On Behalf of the AATF
“Drug options for treatment of infections are becoming increasingly limited, largely as a result of growing antimicrobial resistance. Many generic but essential antibiotics are in short supply, and the development of new antibiotics has been severely curtailed…. Only 4 large pharmaceutical companies with antibiotic research programs remained in existence in 2002….” (Institute of Medicine Report, 2003)
Spellberg et al, CID 2004 in press
Will it be enough?
Anita Manning, Sept 15, 2003
General Scientific Readership
ID Specialty Journals
Change unlikely, without scientific data to justify different usage patterns
For investments in priority antibacterials
Increase Funding for Essential Programs
These considerations to be discussed in detail in IDSA’s White Paper, to be released in May
Bad Bugs, No Drugs….
How Can IDSA Help?
We Want Your Input